HCW Biologics Inc HCWB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
HCW Biologics Announces Pricing of $1.5 Million Private Placement
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
Trading Information
- Previous Close Price
- $0.76
- Day Range
- $0.76–0.78
- 52-Week Range
- $0.74–23.94
- Bid/Ask
- $0.77 / $0.78
- Shares Outstanding
- 3.14M
- Market Cap
- $1.73M
- Volume/Avg
- 1,923 / 391,010
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.09
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 35
- Website
- https://www.hcwbiologics.com
Valuation
Metric | HCWB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.17 |
Price/Sales | 0.09 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | HCWB |
|---|---|
Quick Ratio | 0.04 |
Current Ratio | 0.06 |
Interest Coverage | −7.64 |
Quick Ratio
HCWB
Profitability
Metric | HCWB |
|---|---|
Return on Assets (Normalized) | −6.89% |
Return on Equity (Normalized) | −66.46% |
Return on Invested Capital (Normalized) | −12.95% |
Return on Assets
HCWB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|!xrjv% | LOCK|lrRB | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|QHS!V< | LOCK|%D@& | $98B | |||
| Moderna Inc MRNA | LOCK|!<?H>j | LOCK|Zd | $80B | |||
| argenx SE ADR ARGX | LOCK|^X&!ss | LOCK|$?N | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!H^&!B> | LOCK|^Y@ | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|WT>BtYW | LOCK|%^FJ@ | $31B | |||
| Incyte Corp INCY | LOCK|wcgq<@ | LOCK|d& | $24B | |||
| BioNTech SE ADR BNTX | LOCK|f^VM$z> | LOCK|!gb | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|t$YfFNc | LOCK|?fWf | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|NQ#fd< | LOCK|np | $16B |